Insulin Degludec and Liraglutide Interaction

Understanding the Insulin Degludec and Liraglutide Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Insulin Degludec belongs to the Ultra-Long-Acting Insulin class and Liraglutide belongs to the GLP-1 Receptor Agonist class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Liraglutide slows down the movement of food and medicine through your stomach, which can change how your body absorbs pills. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Insulin Degludec has 12 total documented interactions on file in this dataset, and Liraglutide has 1. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Be careful when taking oral medicines with this drug and watch for changes in how well your other medicines work. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Insulin Degludec or Liraglutide based on a web page, speak with your prescriber or pharmacist before making any change.